i did a google and found that 17 April, 2009 (16:00:00 AEST)
Prima Biomed increases issued capital by 0.6% April 17, 2009 16:00:00 AEST
Prima Biomed (PRR.AU) has announced an increase of 2,000,000 shares (or 0.6%) in total Share on issue from 344,679,915 to 346,679,915. The effective date is 17 Apr, 2009. The stock price plummeted 0.30c (or 8.6%) close at 3.20c, ending a four-day streak of rises. Compared with the All Ordinaries index which rose 2.5 points (or 0.1%) on the day, this was a relative price change of -8.6%.
ISSUED CAPITAL Based on 346,679,915 issued shares the market capitalisation is $11.1 million. It is Australia's 53rd largest Biotechnology company by total revenue.
OPTIONS [PRRO:$2.0] There are 139,693,305 options on issue representing 40.3% of total shares on issue. The exercise price of the options is $2.0 and the exercise date is 31/12/2011 [987 days to expire]. Having potentially dilutive options above 7% of issued shares is not considered desirable by Warren Buffett. Price Trend: [price change of PRR in brackets] PRRO slumped 6.2% for the day [8.6%]; soared 275.0% for the week [100.0%]; soared 400.0% for the month [128.6%] and soared 150.0% for the year [166.7%].
PRICE VOLUME DYNAMICS Volatility: the stock traded between an intraday high of 3.90c and a two-day low of 3.0c, suggesting a trading opportunity between peaks and troughs. Relativities: today its percentile rank in the Australian market was 5. In the Australian market of 1,268 stocks traded today, the stock has a 6-month relative strength of 99 which means it is beating 99% of the market. Volume: there were 21,993,526 shares worth $76.2 million traded. The volume was 15.97 times average trading of 1,377,127 shares. % Discount to high: the last price is at a discount of 20.0% to the 12-month high of 4.0c one-day ago on 16 Apr, 2009. Beta is 3.1.
PRICE PERFORMANCE RANK IN INDEX AND SECTORS The stock is in 1 index and 2 sectors. The stock went against the trend set by the following index and sectors (rank by percentage price change of stock for 1 day;6 months in sector/index in brackets): Biotechnology sector (rank 22;2 out of 29) was up 69.8 points or 1.2% to 5,773.7, Total Australian Market (rank 1213;12 out of 1734) was up 7.7 points or 0.2% to 4,455.9, All Ordinaries index was up 2.5 points or 0.1% to 3,728.
Description % Ch 1-D Rank 1-D % Ch 6-Mo Rank 6-Mo Total Prima Biomed -8.6 300.0 All Ordinaries index 0.1 -5.5 434 Biotechnology sector 1.2 22 1.2 2 29 Total Australian Market 0.2 1213 0.2 12 1734
RELATIVE VALUATION INDICATORS [RVI] FUNDAMENTAL ANALYSIS Bullish Signals: - The Price to Book of 4.8 lower than average of 8.9 for the Total Australian Market. Bearish Signals: - Price/Sales of 168.49 versus sector average of 31.9 and market average of 31.9. - Return on Equity of -71.7% versus sector average of 27.1% and market average of 22.1%. - Return on Assets of -66.9% versus sector average of 23.5% and market average of 8.3%.
RELATIVE VALUATION INDICATORS [RVI] TECHNICAL ANALYSIS Bullish Signals: - The price soared 100.0% in the last week and 128.6% in the last month. - This has been propped up by extraordinary volume of 14.0 times average for the week and by strong volume 6.2 times average for the month. - In the Australian market of 1,268 stocks traded today, the stock has a 6-month relative strength of 99 which means it is beating 99% of the market. - In the last three months the stock has hit a new 52-week high thrice. Bearish Signals: - In the last three months the stock has hit a new 52-week low twenty-one times, pointing to a significant downtrend.
SHAREHOLDER RETURNS Trailing one week: the stock rose four times (80% of the time) and fell once (20% of the time). The volume was 14.0 times average trading of 6,885,635 shares. The value of $1,000 invested a week ago is $2,133 [vs $1,031 for the All Ordinaries index], for a capital gain of $1,133(or rise of 113.3%). Trailing one month: the stock rose ten times (48% of the time), fell eight times (38% of the time) and was unchanged three times (14% of the time). The volume was 6.2 times average trading of 30,296,794 shares. The value of $1,000 invested a month ago is $2,286 [vs $1,100 for the All Ordinaries index], for a capital gain of $1,286(or rise of 128.6%). Trailing one year: the value of $1,000 invested one year ago is $2,667 [vs $704 for the All Ordinaries index], for a capital gain of $1,667. The total return to shareholders for 1 year is 166.7%.
FINANCIALS Half Yearly Report released on March 17, 2009; year-on-year comparisons with previous corresponding period: In the half year to December 31, 2008 total revenue was up 59.1% to $22,679; net loss of $807,036.
FUNDAMENTALS P/S: the price/sales ratio is 168.5. Price to NTA: The net tangible asset backing per share is 0.67c. The price to net tangible asset backing per share is 4.8.
ACTIVITIES Prima BioMed is an Australian biotechnology company with a portfolio of products focussed in the therapeutic area of cancer.
BUSINESS NEWS ROUND UP The last 5 snippets from News Bites are: April 15: Prima Biomed director acquires 498k shares Prima Biomed Ltd director Martin Rogers indirectly acquired 497,500 shares for $9,950 via off-market transfer on April 14.He indirectly holds 497,500 shares and 18,000,000 options.
March 26: Prima BioMed patents cancer treatment in Europe Prima BioMed Ltd subsidiary Cancer Vac Pty Ltd has been granted a patent covering the administration of Prima's ovarian cancer immunotherapy product CVac by the European Patent Office.CVac is a therapy treatment administered post-surgery and post-chemotherapy to delay relapse and control metastases.Prima says it is making rapid progress towards commercialising CVac into the global multi-billion oncology pharmacy market.The new patent claims are granted under patent number 1027063, entitled "Compositions for immunotherapy".
March 25: Prima Biomed trading halt (Updated) Prima Biomed Ltd requested a trading halt on March 25, pending an announcement regarding the grant of a patent.Trading will resume on March 27 or on an earlier announcement.
March 25: Prima Biomed trading halt Prima Biomed Ltd requested a trading halt on March 25, pending an announcement.Trading will resume on March 27 or on an earlier announcement.
March 11: Prima Biomed secures $12m funding for cancer treatment Prima Biomed Ltd has secured a $12 million funding facility with investment bank Fortrend Securities Pty Ltd to advance the commercialisation of Prima's headline CVac ovarian cancer treatment product. The funding will be provided by an equity draw down facility provided by Fortrend, which will allow Prima to place shares with Fortrend over the next 3 years.The funding is a milestone for Prima as it enters the final stage of commercialisation of CVac.
Currency Conversion: Australian Dollar AUD 1 = US$ 0.7164 [or US$1=AUD 1.4]; Against the US$ the AUD slumped 114.53 basis points (or 1.1%) for the day; weakened 0.4% for the week; increased 1.9% for the month; crashed 21.6% in the past year. $ 1 = 100c.
Source: www.BuySellSignals.com
PRR Price at posting:
2.7¢ Sentiment: None Disclosure: Held
(20min delay)